261007 – ACE Inhibitors and Kidney Failure

October 7, 2026 Leave a comment

ACE Inhibitors and Kidney Failure: Cause, Cure, or Bystander?

· @Thomas Lee Abshier, ND

The short answer

ACE inhibitors slow the long-term loss of kidney function in most people with kidney disease, yet they can also cause sudden kidney injury in a predictable set of circumstances. When a patient on an ACE inhibitor reaches kidney failure, the underlying disease is usually the main cause. The drug becomes a contributor when it is combined with dehydration, NSAIDs, diuretics, narrowed kidney arteries, or a second drug of the same kind.

The question matters because ACE inhibitors (captopril, enalapril, lisinopril, ramipril, benazepril, and others) are among the most prescribed drugs worldwide. They are given precisely to people at highest risk of kidney failure: those with long-standing hypertension, diabetes, heart failure, or protein in the urine. Many such patients will lose kidney function whatever they take, so seeing the drug in the chart of a dialysis patient does not by itself show that the drug caused the failure. Physicians call this confounding by indication.

This article explains how the drug affects the kidney, what the trials show, when harm occurs, and how to tell the two apart in an individual patient.

How ACE inhibitors change kidney filtration

The same action that protects the kidney over years is what lowers its filtering rate in the short term.

Each of the roughly one million filtering units in a kidney, the glomeruli, sits between two small arteries. Blood enters through the afferent arteriole and leaves through the efferent arteriole. The pressure inside the glomerulus, which drives filtration, depends on the balance between the two.

Angiotensin II, which ACE inhibitors reduce, constricts the outflow (efferent) arteriole more than the inflow one. That backs pressure up into the glomerulus and keeps filtration high even when blood flow to the kidney falls. When an ACE inhibitor lowers angiotensin II, the outflow vessel relaxes, glomerular pressure drops, and the glomerular filtration rate (GFR) falls. Blood creatinine rises accordingly.

Why this protects in the long run. Persistently high glomerular pressure stretches and scars the filters. It is a major route by which diabetes and hypertension destroy kidneys. Lowering that pressure reduces protein leakage and slows scarring. A modest early creatinine rise of up to about 30% after starting the drug is expected and was associated with better long-term preservation of kidney function in trial analyses.

Why this can injure. Some kidneys can only keep filtering because angiotensin II is holding glomerular pressure up. This happens when narrowed arteries, dehydration, low cardiac output, or drugs that constrict the inflow vessel reduce blood flow into the kidney. Remove angiotensin II in those kidneys and filtration can collapse within days.

ACE inhibitors also block the breakdown of bradykinin, which widens blood vessels. This contributes to the drug’s effect on blood pressure, its typical dry cough, and rarely angioedema, but it is not a major driver of kidney injury.

Evidence that they protect kidneys

In randomized trials, ACE inhibitors reduced progression to kidney failure by roughly 40–50% in patients with proteinuric kidney disease.

Trial Patients Drug Main kidney result
Lewis et al., NEJM 1993 409 with type 1 diabetic nephropathy Captopril vs placebo About 48% lower risk of creatinine doubling; about half the risk of death, dialysis, or transplant
AIPRI, Maschio et al., NEJM 1996 583 with moderate chronic renal insufficiency Benazepril vs placebo 53% lower risk of creatinine doubling or dialysis over 3 years
REIN, GISEN group, Lancet 1997 Non-diabetic disease with heavy proteinuria Ramipril vs placebo plus other drugs Slower GFR decline; trial stopped early for benefit
Hou et al., NEJM 2006 224 non-diabetic patients, creatinine 3.1–5.0 mg/dL Benazepril vs placebo 43% lower risk of doubling, dialysis, or death; 40% lower risk of end-stage disease

The angiotensin receptor blockers, a closely related class, showed similar benefit in type 2 diabetic nephropathy in the RENAAL and IDNT trials of 2001.

Limits of this evidence. Trial patients were screened and closely monitored. People with known renal artery stenosis or unstable kidney function were often excluded, and creatinine and potassium were checked repeatedly in the first weeks. For example, Hou’s patients were closely monitored during the first eight weeks to catch early harm. Ordinary practice is less careful, so trial results show what the drug can do when used well, not necessarily what it does in every patient. The benefit is also greatest in people who leak protein in the urine; it is smaller and less certain in those who do not.

When they harm: acute kidney injury

ACE inhibitors cause kidney injury mainly when something else has already reduced blood flow into the kidney. Each of the following settings is well documented.

1. Narrowed kidney arteries. Renal artery stenosis in both kidneys, or in the artery to a single working kidney, is the classic cause of ACE-inhibitor kidney failure; it was described in NEJM in 1983 shortly after captopril came into use. A narrowed artery lowers pressure to the kidney, and angiotensin II helps keep that kidney filtering. Atherosclerotic stenosis is common in exactly the older, hypertensive, diabetic, smoking patients who receive these drugs, and it is often undiagnosed. An unexplained creatinine jump of more than 30% after starting the drug should prompt a search for it.

2. Volume depletion. Vomiting, diarrhea, poor fluid intake, summer heat, or over-diuresis lower kidney blood flow. In a patient continuing an ACE inhibitor through such an illness, filtration can fall sharply. Many cases of drug-associated kidney injury begin with an ordinary stomach virus.

3. The “triple whammy.” NSAIDs such as ibuprofen, naproxen, and diclofenac constrict the inflow arteriole, while ACE inhibitors relax the outflow arteriole and diuretics reduce blood volume. Together they attack glomerular pressure from three sides. In a UK study of more than 487,000 people on blood-pressure drugs (Lapi et al., BMJ 2013), this triple combination raised the rate of acute kidney injury by 31% overall and by 82% in the first 30 days. Double combinations did not measurably raise risk. Many patients buy NSAIDs over the counter without telling their physician.

4. Dual blockade. Combining an ACE inhibitor with an angiotensin receptor blocker or aliskiren was once promoted to further reduce protein leakage. The ONTARGET trial (Lancet 2008) found more dialysis, creatinine doubling, and death with the combination, and VA NEPHRON-D (NEJM 2013) was stopped early because of excess kidney injury and high potassium. Dual blockade is now advised against.

5. Low cardiac output and liver disease. Advanced heart failure and cirrhosis reduce effective blood flow to the kidneys, making filtration dependent on angiotensin II. ACE inhibitors are still valuable in heart failure but require slow dose increases and close monitoring.

6. Contrast dye and major surgery. Some clinicians hold ACE inhibitors around iodinated contrast studies and major operations because of low blood pressure and kidney stress. Evidence for routinely stopping them is mixed, but the concern is reasonable in patients with other risk factors.

From acute injury to permanent loss. These injuries are usually reversible if the drug is stopped and fluid is restored promptly. Each episode of acute injury, however, raises the later risk of chronic kidney disease, and a kidney already scarred by diabetes or hypertension has less reserve to recover. Repeated or unrecognized episodes can therefore accelerate a patient toward dialysis. This is the most plausible way an ACE inhibitor contributes to permanent kidney failure.

The advanced-kidney-disease question

The best current evidence says that stopping ACE inhibitors in advanced kidney disease does not slow the decline toward dialysis.

For years nephrologists debated whether ACE inhibitors should be withdrawn once GFR falls below about 30. The reasoning was sound: if the drug lowers filtration pressure, removing it might buy a few points of GFR and delay dialysis. A 2010 observational report by Ahmed and colleagues described 52 patients whose GFR rose after stopping, and many clinicians began stopping the drugs routinely.

The question was then tested directly. The STOP-ACEi trial randomized 411 patients with advanced, progressive kidney disease (eGFR below 30) to stop or continue their ACE inhibitor or receptor blocker. After three years there was no significant difference in kidney function, and no subgroup by age, diabetes, protein leakage, or blood pressure showed benefit from stopping (Bhandari et al., NEJM 2022). Blood pressure and proteinuria were higher in the stopping group during the first year or so.

Combined with Hou’s 2006 benazepril trial in stage 4 disease, this evidence does not support the idea that ACE inhibitors drive late-stage kidney failure. It also does not show that every patient benefits. Judge the drug patient by patient: stopping remains appropriate during acute illness, for dangerous potassium levels, or when an unexplained sharp creatinine rise follows a dose change.

Rare direct toxicity, potassium, and pregnancy

Aside from the pressure effect, three other kidney-related harms are recognized.

  • Immune kidney injury. Captopril, which carries a sulfhydryl group like penicillamine, was linked in its early high-dose years to membranous nephropathy and protein leakage. Allergic interstitial nephritis has been reported with several ACE inhibitors. Both are rare and usually improve after stopping the drug.
  • High potassium. By lowering aldosterone, ACE inhibitors raise blood potassium. The risk is greatest with existing kidney disease, diabetes, potassium supplements or salt substitutes, potassium-sparing diuretics such as spironolactone, and NSAIDs. Severe hyperkalemia can stop the heart, and it is a frequent reason the drug must be reduced or stopped.
  • Pregnancy. ACE inhibitors damage the developing fetal kidney, especially in the second and third trimesters, causing low amniotic fluid, kidney malformation, and newborn kidney failure. They should be stopped as soon as pregnancy is recognized, and women who may become pregnant should be counseled before starting.

Reading a patient’s history: drug or disease?

The timing and shape of the kidney decline are the strongest clues to whether the drug or the disease was responsible.

Finding Points toward the drug Points toward the disease
Timing Creatinine rose sharply within days to weeks of starting or increasing the drug Gradual decline over years
Trigger Decline began during vomiting, diarrhea, dehydration, heat, or a new diuretic No acute event
Other drugs NSAID use (often over the counter), dual blockade, potassium-sparing diuretic None of these
Response to stopping Creatinine fell back toward baseline within days to weeks No improvement after stopping
Arteries Renal artery stenosis found, or unequal kidney sizes on ultrasound Normal arteries
Underlying diagnosis Little prior kidney disease Diabetic nephropathy, hypertensive nephrosclerosis, glomerulonephritis, polycystic kidneys
Urine Little protein; bland sediment Heavy, rising proteinuria before the drug was started

Most patients who reach dialysis while taking an ACE inhibitor fall mainly in the right-hand column. A mixed picture is common: a kidney steadily damaged by diabetes may be pushed over the edge by an episode of dehydration while the drug and an NSAID were continued. In such cases the drug did not cause the disease, but it may have shortened the time to dialysis.

For patients who have had a transplant, the native kidney biopsy or the nephrologist’s working diagnosis usually settles the question. Diabetic and hypertensive kidney disease together account for most kidney failure in the United States.

Practical safeguards

Most ACE-inhibitor kidney injury is preventable with a few simple habits.

For clinicians

  • Check creatinine and potassium before starting, then one to two weeks after starting or raising the dose.
  • Accept a creatinine rise of up to about 30% if it stabilizes. Investigate anything larger for renal artery stenosis, volume depletion, or NSAID use.
  • Avoid combining an ACE inhibitor with an angiotensin receptor blocker or aliskiren.
  • Ask specifically about over-the-counter NSAIDs and avoid the diuretic-plus-ACE inhibitor-plus-NSAID combination, especially in older patients.
  • Recheck kidney function after any acute illness, hospital stay, or new diuretic.

For patients: “sick-day rules”

  • During vomiting, diarrhea, fever with poor intake, or heavy sweating, pause the ACE inhibitor, any diuretic, and any NSAID until you eat and drink normally for 24 to 48 hours, then restart. Agree on this plan with your prescriber in advance.
  • Use acetaminophen rather than ibuprofen or naproxen for pain unless your physician approves otherwise, and keep to labeled doses.
  • Avoid potassium-based salt substitutes and potassium supplements unless prescribed.
  • If you could become pregnant, discuss contraception or an alternative drug before starting.
  • Do not stop the drug permanently on your own; for most people with kidney disease it is protective.

Conclusion

ACE inhibitors are neither the hidden cause of the kidney-failure epidemic nor harmless. Across decades of trials they have slowed kidney decline, especially in diabetic and protein-leaking disease, and stopping them late in kidney disease does not help. Their real danger is a sudden collapse of filtration when kidney blood flow is already compromised, most often by dehydration, NSAIDs combined with diuretics, or undiagnosed renal artery stenosis. Recognized promptly, these injuries usually reverse. Unrecognized and repeated, they can hasten a damaged kidney toward dialysis.

For patients who reached kidney failure while taking these drugs, the honest answer is usually that the underlying disease did most of the damage, with the drug sometimes contributing during acute episodes. The timing of the decline, the presence of triggers, and the underlying diagnosis are what decide each case.

This article is for education and is not medical advice. Patients should not start or stop a prescription medication without consulting the prescribing clinician.

Sources

Leave a Reply

Your email address will not be published. Required fields are marked *